Received Mar 13, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| VARZOS | ZOSTER (SHINGRIX) | GLAXOSMITHKLINE BIOLOGICALS | 2 | — | — |
| VARZOS | ZOSTER (SHINGRIX) | GLAXOSMITHKLINE BIOLOGICALS | 1 | — | — |
No titers; This non-serious case was reported by a other health professional via call center representative and described the occurrence of therapy non-responder in a patient who received Herpes zoster (Shingrix) for prophylaxis. Co-suspect products included Herpes zoster (Shingrix) for prophylaxis. On an unknown date, the patient received the 2nd dose of Shingrix and the 1st dose of Shingrix. On an unknown date, 1 year after receiving Shingrix and an unknown time after receiving Shingrix, the patient experienced therapy non-responder (Verbatim: No titers). The outcome of the therapy non-responder was not applicable. Additional Information: GSK Receipt Date: 06-MAR-2025 The Shingrix information for a patient vaccinated with Shingrix, two doses, and showed no titers on a standard lab test 1 year later. The reporter asked was there a specific lab test to show immunity for Shingrix. The Vaccine Administration Facility was the same as Primary Reporter.